Glycogen hyperphosphorylation underlies lafora body formation
- PMID: 21077101
- DOI: 10.1002/ana.22156
Glycogen hyperphosphorylation underlies lafora body formation
Abstract
Objective: Glycogen, the largest cytosolic macromolecule, acquires solubility, essential to its function, through extreme branching. Lafora bodies are aggregates of polyglucosan, a long, linear, poorly branched, and insoluble form of glycogen. Lafora bodies occupy vast numbers of neuronal dendrites and perikarya in Lafora disease in time-dependent fashion, leading to intractable and fatal progressive myoclonus epilepsy. Lafora disease is caused by deficiency of either the laforin glycogen phosphatase or the malin E3 ubiquitin ligase. The 2 leading hypotheses of Lafora body formation are: (1) increased glycogen synthase activity extends glycogen strands too rapidly to allow adequate branching, resulting in polyglucosans; and (2) increased glycogen phosphate leads to glycogen conformational change, unfolding, precipitation, and conversion to polyglucosan. Recently, it was shown that in the laforin phosphatase-deficient form of Lafora disease, there is no increase in glycogen synthase, but there is a dramatic increase in glycogen phosphate, with subsequent conversion of glycogen to polyglucosan. Here, we determine whether Lafora bodies in the malin ubiquitin ligase-deficient form of the disease are due to increased glycogen synthase or increased glycogen phosphate.
Methods: We generated malin-deficient mice and tested the 2 hypotheses.
Results: Malin-deficient mice precisely replicate the pathology of Lafora disease with Lafora body formation in skeletal muscle, liver, and brain, and in the latter in the pathognomonic perikaryal and dendritic locations. Glycogen synthase quantity and activity are unchanged. There is a highly significant increase in glycogen phosphate.
Interpretation: We identify a single common modification, glycogen hyperphosphorylation, as the root cause of Lafora body pathogenesis.
Similar articles
-
Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.Hum Mol Genet. 2004 Jun 1;13(11):1117-29. doi: 10.1093/hmg/ddh130. Epub 2004 Apr 21. Hum Mol Genet. 2004. PMID: 15102711
-
Laforin in autophagy: a possible link between carbohydrate and protein in Lafora disease?Autophagy. 2010 Nov;6(8):1229-31. doi: 10.4161/auto.6.8.13307. Autophagy. 2010. PMID: 20818153
-
Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.Brain. 2022 Jul 29;145(7):2361-2377. doi: 10.1093/brain/awac017. Brain. 2022. PMID: 35084461 Free PMC article.
-
Advances in lafora progressive myoclonus epilepsy.Curr Neurol Neurosci Rep. 2007 Sep;7(5):428-33. doi: 10.1007/s11910-007-0066-7. Curr Neurol Neurosci Rep. 2007. PMID: 17764634 Review.
-
Lafora disease: Current biology and therapeutic approaches.Rev Neurol (Paris). 2022 Apr;178(4):315-325. doi: 10.1016/j.neurol.2021.06.006. Epub 2021 Jul 21. Rev Neurol (Paris). 2022. PMID: 34301405 Free PMC article. Review.
Cited by
-
Glycogen and its metabolism: some new developments and old themes.Biochem J. 2012 Feb 1;441(3):763-87. doi: 10.1042/BJ20111416. Biochem J. 2012. PMID: 22248338 Free PMC article. Review.
-
Lafora bodies in skeletal muscle are fiber type specific.Neurology. 2011 May 10;76(19):1674-6. doi: 10.1212/WNL.0b013e318219faf6. Epub 2011 Mar 30. Neurology. 2011. PMID: 21451149 Free PMC article. No abstract available.
-
Neurological glycogen storage diseases and emerging therapeutics.Neurotherapeutics. 2024 Sep;21(5):e00446. doi: 10.1016/j.neurot.2024.e00446. Epub 2024 Sep 14. Neurotherapeutics. 2024. PMID: 39277505 Free PMC article. Review.
-
Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.Biochem J. 2011 Oct 15;439(2):265-75. doi: 10.1042/BJ20110150. Biochem J. 2011. PMID: 21728993 Free PMC article.
-
Generation and characterization of a laforin nanobody inhibitor.Clin Biochem. 2021 Jul;93:80-89. doi: 10.1016/j.clinbiochem.2021.03.017. Epub 2021 Apr 5. Clin Biochem. 2021. PMID: 33831386 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases